This week, the court struck down the decision to let Myriad patent the BRCA1 and BRCA2 genes- the genes associated with hereditary breast and ovarian cancers. We received questions about what this decision means for people with cancer. Dr. Adam Clark, director of science and policy at the foundation, addresses those questions in the video below. Please feel free to leave any additional questions in the comments section. We will do our best to answer them directly.